Product was Puma Biotechnology’s largest product and service line in fiscal 2025, bringing in $204.07M of $228.37M (89%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Product | $200.02M | $203.11M | $195.19M | $204.07M | ||||||
| Product Revenue, Net | — | — | — | — | ||||||
| License | — | — | — | — | ||||||
| License Revenue | — | — | — | — | ||||||
| Royalty | $28.01M | $32.53M | $35.28M | $24.30M | ||||||
| Total | $228.03M | $235.64M | $230.47M | $228.37M |
Puma Biotechnology brought in $228.37M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 0.9% from $230.47M in fiscal 2024. Product was the largest at $204.07M (89.4%), ahead of Royalty at $24.30M (10.6%).
Compared with fiscal 2024, Product grew 4.6% to $204.07M, while Royalty fell 31.1% to $24.30M. From fiscal 2022 to 2025, combined revenue from these lines grew from $228.03M to $228.37M, a compound annual growth rate of 0.0%. Product's share of the total rose from 87.7% to 89.4%.
Puma Biotechnology (PBYI) reports its revenue by product and service. In fiscal 2025, Product was its largest product and service line, bringing in $204.07M (89.4% of the total), followed by Royalty at $24.30M (10.6%).
Product was Puma Biotechnology's largest product and service line in fiscal 2025, bringing in $204.07M, or 89.4% of the $228.37M total across its two product and service lines.
Product grew faster than Royalty in fiscal 2025, up 4.6% from $195.19M to $204.07M. Royalty fell 31.1% to $24.30M.
Every figure comes from Puma Biotechnology's annual financial filings, as reported. Each line keeps the name Puma Biotechnology gives it, and years follow its fiscal calendar.
Puma Biotechnology's revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.